 Cyclerion Therapeutics, Inc. CYCN, a clinical-stage biopharmaceutical company focused on the development of soluble guanylate cyclase sGC stimulators for the treatment of serious and orphan diseases, today announced that it will host a webcast investor event, to be held in New York City, on Tuesday, September 17, 2019 from 8:00 a.m. to 10:00 a.m. Eastern Time. This first Cyclerion live investor event will focus on praliciguat, the companys investigational, orally administered, once-daily systemic sGC stimulator designed for the treatment of serious cardiometabolic diseases. External subject matter experts Dr. James Udelson of Tufts Medical Center and Dr. Barbara Gillespie of the University of North Carolina and Covance and members of Cyclerions leadership team will review the role of the nitric oxidesGC system in cardiorenal physiology, the praliciguat development program, and the ongoing Phase 2 clinical studies investigating praliciguat as a potential treatment for diabetic nephropathy and for HFpEF. 